2023
Complex Percutaneous Coronary Intervention Outcomes in Older Adults
Hanna J, Wang S, Kochar A, Park D, Damluji A, Henry G, Ahmad Y, Curtis J, Nanna M. Complex Percutaneous Coronary Intervention Outcomes in Older Adults. Journal Of The American Heart Association 2023, 12: e029057. PMID: 37776222, PMCID: PMC10727245, DOI: 10.1161/jaha.122.029057.Peer-Reviewed Original ResearchConceptsNoncomplex percutaneous coronary interventionsComplex percutaneous coronary interventionStable ischemic heart diseasePercutaneous coronary interventionIschemic heart diseaseTarget lesion revascularizationEvent-free survivalHeart diseaseOlder adultsCause deathLesion revascularizationClinical characteristicsElective percutaneous coronary interventionPercutaneous coronary intervention outcomesWorse event-free survivalMedical therapy useCox regression modelLarge health systemNoncardiac comorbiditiesRevascularization riskCoronary interventionTherapy useClinical outcomesDisease featuresLower risk
2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trials